Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring
Background Despite a lack of clinical evidence, hydroxychloroquine and azithromycin are being administered widely to patients with verified or suspected coronavirus disease 2019 (COVID‐19). Both drugs may increase risk of lethal arrhythmias associated with QT interval prolongation. Methods and Resul...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-06-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.120.017144 |
| _version_ | 1811332370088853504 |
|---|---|
| author | Archana Ramireddy Harpriya Chugh Kyndaron Reinier Joseph Ebinger Eunice Park Michael Thompson Eugenio Cingolani Susan Cheng Eduardo Marban Christine M. Albert Sumeet S. Chugh |
| author_facet | Archana Ramireddy Harpriya Chugh Kyndaron Reinier Joseph Ebinger Eunice Park Michael Thompson Eugenio Cingolani Susan Cheng Eduardo Marban Christine M. Albert Sumeet S. Chugh |
| author_sort | Archana Ramireddy |
| collection | DOAJ |
| description | Background Despite a lack of clinical evidence, hydroxychloroquine and azithromycin are being administered widely to patients with verified or suspected coronavirus disease 2019 (COVID‐19). Both drugs may increase risk of lethal arrhythmias associated with QT interval prolongation. Methods and Results We analyzed a case series of COVID‐19–positive/suspected patients admitted between February 1, 2020, and April 4, 2020, who were treated with azithromycin, hydroxychloroquine, or a combination of both drugs. We evaluated baseline and postmedication QT interval (corrected QT interval [QTc]; Bazett) using 12‐lead ECGs. Critical QTc prolongation was defined as follows: (1) maximum QTc ≥500 ms (if QRS <120 ms) or QTc ≥550 ms (if QRS ≥120 ms) and (2) QTc increase of ≥60 ms. Tisdale score and Elixhauser comorbidity index were calculated. Of 490 COVID‐19–positive/suspected patients, 314 (64%) received either/both drugs and 98 (73 COVID‐19 positive and 25 suspected) met study criteria (age, 62±17 years; 61% men). Azithromycin was prescribed in 28%, hydroxychloroquine in 10%, and both in 62%. Baseline mean QTc was 448±29 ms and increased to 459±36 ms (P=0.005) with medications. Significant prolongation was observed only in men (18±43 ms versus −0.2±28 ms in women; P=0.02). A total of 12% of patients reached critical QTc prolongation. Changes in QTc were highest with the combination compared with either drug, with much greater prolongation with combination versus azithromycin (17±39 ms versus 0.5±40 ms; P=0.07). No patients manifested torsades de pointes. Conclusions Overall, 12% of patients manifested critical QTc prolongation, and the combination caused greater prolongation than either drug alone. The balance between uncertain benefit and potential risk when treating COVID‐19 patients should be carefully assessed. |
| first_indexed | 2024-04-13T16:35:50Z |
| format | Article |
| id | doaj.art-0d3e5aa010dc418ea8a46c281b8e15c2 |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-04-13T16:35:50Z |
| publishDate | 2020-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-0d3e5aa010dc418ea8a46c281b8e15c22022-12-22T02:39:26ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802020-06-0191210.1161/JAHA.120.017144Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval MonitoringArchana Ramireddy0Harpriya Chugh1Kyndaron Reinier2Joseph Ebinger3Eunice Park4Michael Thompson5Eugenio Cingolani6Susan Cheng7Eduardo Marban8Christine M. Albert9Sumeet S. Chugh10The Smidt Heart Institute, Cedars‐Sinai Health System Los Angeles CAThe Smidt Heart Institute, Cedars‐Sinai Health System Los Angeles CAThe Smidt Heart Institute, Cedars‐Sinai Health System Los Angeles CAThe Smidt Heart Institute, Cedars‐Sinai Health System Los Angeles CAEnterprise Information Systems Data Intelligence Team Cedars‐Sinai Health System Los Angeles CAEnterprise Information Systems Data Intelligence Team Cedars‐Sinai Health System Los Angeles CAThe Smidt Heart Institute, Cedars‐Sinai Health System Los Angeles CAThe Smidt Heart Institute, Cedars‐Sinai Health System Los Angeles CAThe Smidt Heart Institute, Cedars‐Sinai Health System Los Angeles CAThe Smidt Heart Institute, Cedars‐Sinai Health System Los Angeles CAThe Smidt Heart Institute, Cedars‐Sinai Health System Los Angeles CABackground Despite a lack of clinical evidence, hydroxychloroquine and azithromycin are being administered widely to patients with verified or suspected coronavirus disease 2019 (COVID‐19). Both drugs may increase risk of lethal arrhythmias associated with QT interval prolongation. Methods and Results We analyzed a case series of COVID‐19–positive/suspected patients admitted between February 1, 2020, and April 4, 2020, who were treated with azithromycin, hydroxychloroquine, or a combination of both drugs. We evaluated baseline and postmedication QT interval (corrected QT interval [QTc]; Bazett) using 12‐lead ECGs. Critical QTc prolongation was defined as follows: (1) maximum QTc ≥500 ms (if QRS <120 ms) or QTc ≥550 ms (if QRS ≥120 ms) and (2) QTc increase of ≥60 ms. Tisdale score and Elixhauser comorbidity index were calculated. Of 490 COVID‐19–positive/suspected patients, 314 (64%) received either/both drugs and 98 (73 COVID‐19 positive and 25 suspected) met study criteria (age, 62±17 years; 61% men). Azithromycin was prescribed in 28%, hydroxychloroquine in 10%, and both in 62%. Baseline mean QTc was 448±29 ms and increased to 459±36 ms (P=0.005) with medications. Significant prolongation was observed only in men (18±43 ms versus −0.2±28 ms in women; P=0.02). A total of 12% of patients reached critical QTc prolongation. Changes in QTc were highest with the combination compared with either drug, with much greater prolongation with combination versus azithromycin (17±39 ms versus 0.5±40 ms; P=0.07). No patients manifested torsades de pointes. Conclusions Overall, 12% of patients manifested critical QTc prolongation, and the combination caused greater prolongation than either drug alone. The balance between uncertain benefit and potential risk when treating COVID‐19 patients should be carefully assessed.https://www.ahajournals.org/doi/10.1161/JAHA.120.017144azithromycinCOVID‐19hydroxychloroquinemonitoringQT interval |
| spellingShingle | Archana Ramireddy Harpriya Chugh Kyndaron Reinier Joseph Ebinger Eunice Park Michael Thompson Eugenio Cingolani Susan Cheng Eduardo Marban Christine M. Albert Sumeet S. Chugh Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease azithromycin COVID‐19 hydroxychloroquine monitoring QT interval |
| title | Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring |
| title_full | Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring |
| title_fullStr | Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring |
| title_full_unstemmed | Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring |
| title_short | Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring |
| title_sort | experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic implications for qt interval monitoring |
| topic | azithromycin COVID‐19 hydroxychloroquine monitoring QT interval |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.120.017144 |
| work_keys_str_mv | AT archanaramireddy experiencewithhydroxychloroquineandazithromycininthecoronavirusdisease2019pandemicimplicationsforqtintervalmonitoring AT harpriyachugh experiencewithhydroxychloroquineandazithromycininthecoronavirusdisease2019pandemicimplicationsforqtintervalmonitoring AT kyndaronreinier experiencewithhydroxychloroquineandazithromycininthecoronavirusdisease2019pandemicimplicationsforqtintervalmonitoring AT josephebinger experiencewithhydroxychloroquineandazithromycininthecoronavirusdisease2019pandemicimplicationsforqtintervalmonitoring AT eunicepark experiencewithhydroxychloroquineandazithromycininthecoronavirusdisease2019pandemicimplicationsforqtintervalmonitoring AT michaelthompson experiencewithhydroxychloroquineandazithromycininthecoronavirusdisease2019pandemicimplicationsforqtintervalmonitoring AT eugeniocingolani experiencewithhydroxychloroquineandazithromycininthecoronavirusdisease2019pandemicimplicationsforqtintervalmonitoring AT susancheng experiencewithhydroxychloroquineandazithromycininthecoronavirusdisease2019pandemicimplicationsforqtintervalmonitoring AT eduardomarban experiencewithhydroxychloroquineandazithromycininthecoronavirusdisease2019pandemicimplicationsforqtintervalmonitoring AT christinemalbert experiencewithhydroxychloroquineandazithromycininthecoronavirusdisease2019pandemicimplicationsforqtintervalmonitoring AT sumeetschugh experiencewithhydroxychloroquineandazithromycininthecoronavirusdisease2019pandemicimplicationsforqtintervalmonitoring |